Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.

Abstract

NAMI-A is a novel antitumour agent, based on ruthenium, which has proved effectiveness against lung metastases of solid mouse tumours. The study focuses on the effects of NAMI-A on leukocyte infiltration into the primary tumour of MCa mammary carcinoma, implanted subcutaneously (s.c.) or intramuscularly (i.m.) into CBA mice. NAMI-A, given with a cycle of daily treatments for six consecutive days on advanced tumours at 35 mg/kg/day, markedly reduces lung metastasis independently of the tumour type (Lewis lung carcinoma, MCa mammary carcinoma or TS/A adenocarcinoma) being treated and of the site of tumour implantation (s.c. or i.m.). The analysis of leukocyte infiltration of the primary tumour, performed on a single cell suspension of cells isolated from a Ficoll gradient on which a raw suspension of primary tumour cells was layered, showed NAMI-A to significantly increase tumour infiltrating lymphocytes. These lymphocytes are almost all CD3+ cells with a significant increase of the CD8+ over the CD4+ subpopulation that reduces the helper/suppressor ratio from 2.8 to 2.1. These data indicated the absence of toxicity of NAMI-A for tumour infiltrating lymphocytes and suggested that this compound might even synergize in combined treatments with cancer immunotherapy.

• Authors: M Magnarin, A Bergamo, M E Carotenuto, S Zorzet, G Sava
• Journal: Anticancer research (Anticancer Res) 2000 Sep-Oct Vol. 20 Issue 5A Pg. 2939-44 ISSN: 0250-7005 [Print] Greece
• PMID: 11062704 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Organometallic Compounds
• Ruthenium Compounds
• imidazolium-bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III)
• Dimethyl Sulfoxide

Topics

• Adenocarcinoma (drug therapy, immunology)
• Animals
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Lewis Lung (drug therapy, immunology)
• Dimethyl Sulfoxide (analogs & derivatives, therapeutic use)
• Dose-Response Relationship, Drug
• Female
• Humans
• Lung Neoplasms (immunology, prevention & control, secondary)
• Lymphocytes, Tumor-Infiltrating (immunology)
• Mammary Neoplasms, Experimental (drug therapy, immunology)
• Mice
• Mice, Inbred BALB C
• Mice, Inbred CBA
• Organometallic Compounds (therapeutic use)
• Ruthenium Compounds
• T-Lymphocytes (classification, immunology)